Symbols / FOLD
FOLD Chart
About
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.50B |
| Enterprise Value | 4.66B | Income | -27.11M | Sales | 634.21M |
| Book/sh | 0.88 | Cash/sh | 0.94 | Dividend Yield | — |
| Payout | 0.00% | Employees | 511 | IPO | — |
| P/E | — | Forward P/E | 15.62 | PEG | — |
| P/S | 7.09 | P/B | 16.26 | P/C | — |
| EV/EBITDA | 111.03 | EV/Sales | 7.34 | Quick Ratio | 1.72 |
| Current Ratio | 2.84 | Debt/Eq | 161.30 | LT Debt/Eq | — |
| EPS (ttm) | -0.04 | EPS next Y | 0.92 | EPS Growth | -95.50% |
| Revenue Growth | 23.70% | Earnings | 2026-05-07 | ROA | 2.48% |
| ROE | -11.58% | ROIC | — | Gross Margin | 88.50% |
| Oper. Margin | 8.61% | Profit Margin | -4.28% | Shs Outstand | 313.70M |
| Shs Float | 311.41M | Short Float | 5.76% | Short Ratio | 1.84 |
| Short Interest | — | 52W High | 14.38 | 52W Low | 5.51 |
| Beta | 0.43 | Avg Volume | 11.21M | Volume | 2.59M |
| Target Price | $14.50 | Recom | Hold | Prev Close | $14.36 |
| Price | $14.34 | Change | -0.14% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.50
Mean price target
2. Current target
$14.34
Latest analyst target
3. DCF / Fair value
$2.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.34
Low
$14.50
High
$14.50
Mean
$14.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-22 | down | Jefferies | Buy → Hold | $15 |
| 2025-12-29 | down | Leerink Partners | Outperform → Market Perform | $15 |
| 2025-12-22 | down | Citigroup | Buy → Neutral | $15 |
| 2025-12-19 | down | Needham | Buy → Hold | — |
| 2025-12-19 | down | Cantor Fitzgerald | Overweight → Neutral | $15 |
| 2025-12-17 | init | Citigroup | — → Buy | $17 |
| 2025-11-06 | main | JP Morgan | Overweight → Overweight | $19 |
| 2025-11-05 | main | Goldman Sachs | Neutral → Neutral | $11 |
| 2025-09-18 | up | Needham | Hold → Buy | $14 |
| 2025-07-17 | up | Morgan Stanley | Equal-Weight → Overweight | $108 |
| 2025-05-02 | main | UBS | Buy → Buy | $22 |
| 2025-05-02 | main | Goldman Sachs | Neutral → Neutral | $9 |
| 2025-02-20 | main | Wells Fargo | Overweight → Overweight | $17 |
| 2025-02-20 | reit | Needham | Hold → Hold | — |
| 2025-01-15 | reit | Cantor Fitzgerald | Overweight → Overweight | $21 |
| 2025-01-13 | reit | Needham | Hold → Hold | — |
| 2024-12-13 | down | Morgan Stanley | Overweight → Equal-Weight | $12 |
| 2024-11-12 | main | JP Morgan | Overweight → Overweight | $17 |
| 2024-11-07 | main | Guggenheim | Buy → Buy | $15 |
| 2024-11-07 | main | UBS | Buy → Buy | $21 |
- Raise Or Bail? As Netflix Weighs Options In WBD Battle, Its Stock Jumps In Latest Sign Of Investor Angst - Deadline Wed, 25 Feb 2026 20
- Hut 8 Stock Before Q4 Earnings Release: Should You Hold or Fold? - Zacks Investment Research Mon, 23 Feb 2026 16
- Stifel raises BioMarin stock price target to $68 on Fold deal value - Investing.com ue, 24 Feb 2026 12
- Fold (NASDAQ:FLD) CFO Wolfe Repass Sells 12,406 Shares - MarketBeat Wed, 25 Feb 2026 04
- Allot Pre-Q4 Earnings Analysis: Should You Hold or Fold the Stock? - Yahoo Finance Fri, 20 Feb 2026 13
- Precision Trading with Amicus Therapeutics Inc. (FOLD) Risk Zones - Stock Traders Daily ue, 24 Feb 2026 21
- Should Investors Hold or Fold Sterling Stock Ahead of Q4 Earnings? - Nasdaq hu, 19 Feb 2026 13
- Carvana Profit Roars Higher, But Its Stock Price Is Sputtering - Investor's Business Daily Mon, 23 Feb 2026 23
- MercadoLibre Set to Report Q4 Earnings: Hold or Fold the Stock? - Zacks Investment Research Fri, 20 Feb 2026 14
- Amicus Therapeutics (NASDAQ:FOLD) Announces Quarterly Earnings Results - MarketBeat Fri, 20 Feb 2026 21
- Should You Hold or Fold Comfort Systems Stock Ahead of Q4 Earnings? - Yahoo Finance ue, 17 Feb 2026 08
- Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Zacks Investment Research Wed, 11 Feb 2026 08
- TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections - Yahoo Finance hu, 19 Feb 2026 00
- Skillsoft Plummets 75% in a Year: Should You Hold or Fold the Stock? - Yahoo Finance Wed, 11 Feb 2026 08
- NVTS Trades at Premium Valuation: Should You Hold or Fold the Stock? - Yahoo Finance ue, 10 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 75000 | 457500 | — | Conversion of Exercise of derivative security at price 6.10 per share. | CAMPBELL BRADLEY LEWIS | Chief Executive Officer | — | 2026-01-20 00:00:00 | D |
| 1 | 75000 | 1073182 | — | Sale at price 14.31 per share. | CAMPBELL BRADLEY LEWIS | Chief Executive Officer | — | 2026-01-20 00:00:00 | D |
| 2 | 25642 | 363380 | — | Sale at price 14.17 per share. | CLARK DAVID MICHAEL | Officer | — | 2025-12-19 00:00:00 | D |
| 3 | 70426 | 635947 | — | Conversion of Exercise of derivative security at price 9.03 per share. | CAMPBELL BRADLEY LEWIS | Chief Executive Officer | — | 2025-12-15 00:00:00 | D |
| 4 | 25643 | 282073 | — | Sale at price 11.00 per share. | CLARK DAVID MICHAEL | Officer | — | 2025-12-15 00:00:00 | D |
| 5 | 77926 | 846011 | — | Sale at price 10.86 per share. | CAMPBELL BRADLEY LEWIS | Chief Executive Officer | — | 2025-12-15 00:00:00 | D |
| 6 | 32193 | — | — | Stock Award(Grant) at price 0.00 per share. | PROUT SAMANTHA WHITEMAN | Officer | — | 2025-12-01 00:00:00 | D |
| 7 | 14587 | 131721 | — | Conversion of Exercise of derivative security at price 9.03 per share. | CAMPBELL BRADLEY LEWIS | Chief Executive Officer | — | 2025-12-01 00:00:00 | D |
| 8 | 14587 | 146011 | — | Sale at price 10.01 per share. | CAMPBELL BRADLEY LEWIS | Chief Executive Officer | — | 2025-12-01 00:00:00 | D |
| 9 | 95621 | 514786 | — | Conversion of Exercise of derivative security at price 5.13 - 6.10 per share. | ROSENBERG ELLEN S | Officer | — | 2025-11-26 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.93M | -3.71M | -153.88K | -1.83M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.02 | 0.27 |
| NormalizedEBITDA | 38.58M | -74.43M | -191.88M | -196.10M |
| TotalUnusualItems | -9.19M | -17.65M | -7.69M | -6.77M |
| TotalUnusualItemsExcludingGoodwill | -9.19M | -17.65M | -7.69M | -6.77M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -56.11M | -151.58M | -236.57M | -250.46M |
| ReconciledDepreciation | 8.55M | 7.87M | 5.34M | 6.21M |
| ReconciledCostOfRevenue | 52.94M | 37.33M | 38.60M | 34.47M |
| EBITDA | 29.39M | -92.08M | -199.58M | -202.87M |
| EBIT | 20.84M | -99.95M | -204.92M | -209.08M |
| NetInterestIncome | -44.19M | -43.07M | -34.09M | -31.96M |
| InterestExpense | 49.60M | 50.15M | 37.12M | 32.47M |
| InterestIncome | 5.41M | 7.08M | 3.02M | 509.00K |
| NormalizedIncome | -48.85M | -137.64M | -229.03M | -245.52M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -56.11M | -151.58M | -236.57M | -250.46M |
| TotalExpenses | 494.23M | 472.85M | 533.66M | 505.43M |
| TotalOperatingIncomeAsReported | 24.88M | -77.21M | -212.12M | -206.43M |
| DilutedAverageShares | 304.38M | 295.16M | 289.06M | 271.42M |
| BasicAverageShares | 304.38M | 295.16M | 289.06M | 271.42M |
| DilutedEPS | -0.18 | -0.51 | -0.82 | -0.92 |
| BasicEPS | -0.18 | -0.51 | -0.82 | -0.92 |
| DilutedNIAvailtoComStockholders | -56.11M | -151.58M | -236.57M | -250.46M |
| NetIncomeCommonStockholders | -56.11M | -151.58M | -236.57M | -250.46M |
| NetIncome | -56.11M | -151.58M | -236.57M | -250.46M |
| NetIncomeIncludingNoncontrollingInterests | -56.11M | -151.58M | -236.57M | -250.46M |
| NetIncomeContinuousOperations | -56.11M | -151.58M | -236.57M | -250.46M |
| TaxProvision | 27.35M | 1.48M | -5.47M | 8.91M |
| PretaxIncome | -28.76M | -150.10M | -242.04M | -241.55M |
| OtherIncomeExpense | -18.63M | -33.54M | -3.52M | -9.67M |
| OtherNonOperatingIncomeExpenses | -9.44M | -15.89M | 4.18M | -2.90M |
| SpecialIncomeCharges | -9.19M | -17.65M | -7.69M | -6.77M |
| OtherSpecialCharges | 13.93M | 257.00K | ||
| WriteOff | 0.00 | 1.13M | 6.62M | 0.00 |
| RestructuringAndMergernAcquisition | 9.19M | 2.58M | 1.08M | 6.51M |
| NetNonOperatingInterestIncomeExpense | -44.19M | -43.07M | -34.09M | -31.96M |
| InterestExpenseNonOperating | 49.60M | 50.15M | 37.12M | 32.47M |
| InterestIncomeNonOperating | 5.41M | 7.08M | 3.02M | 509.00K |
| OperatingIncome | 34.06M | -73.49M | -204.43M | -199.92M |
| OperatingExpense | 441.29M | 435.52M | 495.06M | 470.97M |
| DepreciationAmortizationDepletionIncomeStatement | 8.55M | 7.87M | 5.34M | 6.21M |
| DepreciationAndAmortizationInIncomeStatement | 8.55M | 7.87M | 5.34M | 6.21M |
| ResearchAndDevelopment | 109.36M | 152.38M | 276.68M | 272.05M |
| SellingGeneralAndAdministration | 323.38M | 275.27M | 213.04M | 192.71M |
| GrossProfit | 475.35M | 362.03M | 290.63M | 271.05M |
| CostOfRevenue | 52.94M | 37.33M | 38.60M | 34.47M |
| TotalRevenue | 528.29M | 399.36M | 329.23M | 305.51M |
| OperatingRevenue | 528.29M | 399.36M | 329.23M | 305.51M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 299.04M | 293.59M | 281.11M | 278.91M |
| ShareIssued | 299.04M | 293.59M | 281.11M | 278.91M |
| NetDebt | 176.36M | 140.86M | 243.18M | 144.16M |
| TotalDebt | 443.64M | 445.06M | 452.12M | 440.13M |
| TangibleBookValue | -20.95M | -58.11M | -97.75M | 86.57M |
| InvestedCapital | 584.16M | 548.03M | 515.04M | 696.73M |
| WorkingCapital | 356.03M | 315.37M | 284.80M | 450.86M |
| NetTangibleAssets | -20.95M | -58.11M | -97.75M | 86.57M |
| CapitalLeaseObligations | 53.53M | 57.20M | 60.13M | 50.77M |
| CommonStockEquity | 194.04M | 160.17M | 123.05M | 307.37M |
| TotalCapitalization | 584.16M | 548.03M | 515.04M | 696.73M |
| TotalEquityGrossMinorityInterest | 194.04M | 160.17M | 123.05M | 307.37M |
| StockholdersEquity | 194.04M | 160.17M | 123.05M | 307.37M |
| OtherEquityInterest | 71.00K | 71.00K | 83.00K | 83.00K |
| GainsLossesNotAffectingRetainedEarnings | 5.09M | 5.24M | -12.11M | 4.98M |
| ForeignCurrencyTranslationAdjustments | 5.30M | 5.43M | -11.99M | 5.25M |
| UnrealizedGainLoss | -207.00K | -188.00K | -116.00K | -270.00K |
| RetainedEarnings | -2.74B | -2.68B | -2.53B | -2.30B |
| AdditionalPaidInCapital | 2.93B | 2.84B | 2.66B | 2.60B |
| CapitalStock | 2.94M | 2.92M | 2.81M | 2.81M |
| CommonStock | 2.94M | 2.92M | 2.81M | 2.81M |
| TotalLiabilitiesNetMinorityInterest | 590.99M | 617.71M | 601.12M | 597.77M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 442.29M | 450.02M | 462.10M | 451.80M |
| OtherNonCurrentLiabilities | 7.10M | 13.28M | 18.53M | 8.24M |
| TradeandOtherPayablesNonCurrent | 1.44M | |||
| NonCurrentDeferredLiabilities | 9.60M | 10.84M | ||
| NonCurrentDeferredTaxesLiabilities | 4.94M | 4.93M | ||
| LongTermDebtAndCapitalLeaseObligation | 435.19M | 436.74M | 443.57M | 432.72M |
| LongTermCapitalLeaseObligation | 45.08M | 48.88M | 51.58M | 43.36M |
| LongTermDebt | 390.11M | 387.86M | 391.99M | 389.36M |
| CurrentLiabilities | 148.70M | 167.69M | 139.02M | 145.97M |
| OtherCurrentLiabilities | 8.71M | 10.37M | 7.46M | 4.20M |
| CurrentDebtAndCapitalLeaseObligation | 8.46M | 8.32M | 8.55M | 7.41M |
| CurrentCapitalLeaseObligation | 8.46M | 8.32M | 8.55M | 7.41M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 32.53M | 38.30M | 25.70M | 24.26M |
| PayablesAndAccruedExpenses | 99.01M | 110.69M | 97.30M | 110.11M |
| CurrentAccruedExpenses | 67.96M | 83.14M | 54.53M | 59.02M |
| InterestPayable | 120.00K | 11.66M | 125.00K | |
| Payables | 31.05M | 27.55M | 42.77M | 51.09M |
| OtherPayable | 21.42M | 23.42M | ||
| TotalTaxPayable | 18.11M | 12.43M | 5.94M | 6.15M |
| AccountsPayable | 12.95M | 15.12M | 15.41M | 21.51M |
| TotalAssets | 785.03M | 777.88M | 724.17M | 905.14M |
| TotalNonCurrentAssets | 280.30M | 294.82M | 300.35M | 308.31M |
| OtherNonCurrentAssets | 13.64M | 18.55M | 19.24M | 24.43M |
| GoodwillAndOtherIntangibleAssets | 215.00M | 218.29M | 220.80M | 220.80M |
| OtherIntangibleAssets | 17.20M | 20.49M | 23.00M | 23.00M |
| Goodwill | 197.80M | 197.80M | 197.80M | 197.80M |
| NetPPE | 51.66M | 57.98M | 60.31M | 63.08M |
| AccumulatedDepreciation | -28.77M | -25.43M | -22.28M | -19.88M |
| GrossPPE | 80.44M | 83.41M | 82.59M | 82.96M |
| Leases | 32.36M | 28.03M | 24.16M | 24.17M |
| ConstructionInProgress | 262.00K | 3.81M | 4.16M | 8.23M |
| OtherProperties | 38.50M | 42.53M | 45.88M | 37.25M |
| MachineryFurnitureEquipment | 9.31M | 9.03M | 8.39M | 10.13M |
| LandAndImprovements | 0.00 | 3.19M | ||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 504.74M | 483.06M | 423.82M | 596.83M |
| OtherCurrentAssets | 34.91M | 49.53M | 40.21M | 34.85M |
| PrepaidAssets | 34.85M | |||
| Inventory | 118.78M | 59.70M | 23.82M | 26.82M |
| FinishedGoods | 9.64M | 6.87M | 4.15M | 3.83M |
| WorkInProcess | 21.22M | 22.60M | 9.62M | 10.70M |
| RawMaterials | 87.92M | 30.23M | 10.05M | 12.29M |
| Receivables | 101.10M | 87.63M | 66.20M | 52.67M |
| AccountsReceivable | 101.10M | 87.63M | 66.20M | 52.67M |
| CashCashEquivalentsAndShortTermInvestments | 249.95M | 286.20M | 293.60M | 482.50M |
| OtherShortTermInvestments | 36.19M | 39.21M | 144.78M | 237.30M |
| CashAndCashEquivalents | 213.75M | 246.99M | 148.81M | 245.20M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -37.44M | -76.53M | -170.34M | -206.38M |
| RepaymentOfDebt | -97.00K | -408.32M | -283.00K | -479.00K |
| IssuanceOfDebt | 0.00 | 387.36M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 19.57M | 92.94M | 0.00 | 199.75M |
| CapitalExpenditure | -3.55M | -7.44M | -3.77M | -3.88M |
| InterestPaidSupplementalData | 58.96M | 36.09M | 34.36M | 30.47M |
| IncomeTaxPaidSupplementalData | 8.21M | 8.53M | 1.07M | 20.03M |
| EndCashPosition | 216.72M | 250.08M | 153.12M | 249.46M |
| BeginningCashPosition | 250.08M | 153.12M | 249.46M | 166.16M |
| EffectOfExchangeRateChanges | -4.03M | 6.31M | -14.62M | -5.05M |
| ChangesInCash | -29.33M | 90.65M | -81.72M | 88.34M |
| FinancingCashFlow | 5.12M | 61.68M | -7.46M | 212.07M |
| CashFlowFromContinuingFinancingActivities | 5.12M | 61.68M | -7.46M | 212.07M |
| NetOtherFinancingCharges | -22.02M | -20.57M | -11.49M | -16.66M |
| ProceedsFromStockOptionExercised | 7.68M | 10.27M | 4.31M | 29.46M |
| NetCommonStockIssuance | 19.57M | 92.94M | 0.00 | 199.75M |
| CommonStockIssuance | 19.57M | 92.94M | 0.00 | 199.75M |
| NetIssuancePaymentsOfDebt | -97.00K | -20.96M | -283.00K | -479.00K |
| NetLongTermDebtIssuance | -97.00K | -20.96M | -283.00K | -479.00K |
| LongTermDebtPayments | -97.00K | -408.32M | -283.00K | -479.00K |
| LongTermDebtIssuance | 0.00 | 387.36M | 0.00 | 0.00 |
| InvestingCashFlow | -560.00K | 98.06M | 92.32M | 78.76M |
| CashFlowFromContinuingInvestingActivities | -560.00K | 98.06M | 92.32M | 78.76M |
| NetOtherInvestingChanges | 3.41M | |||
| NetInvestmentPurchaseAndSale | 2.99M | 105.50M | 92.67M | 82.64M |
| SaleOfInvestment | 117.78M | 197.23M | 335.93M | 424.04M |
| PurchaseOfInvestment | -114.79M | -91.72M | -243.25M | -341.40M |
| CapitalExpenditureReported | -3.55M | -7.44M | -3.77M | -3.88M |
| OperatingCashFlow | -33.89M | -69.09M | -166.57M | -202.49M |
| CashFlowFromContinuingOperatingActivities | -33.89M | -69.09M | -166.57M | -202.49M |
| ChangeInWorkingCapital | -98.94M | -26.64M | -39.88M | -18.59M |
| ChangeInOtherWorkingCapital | -3.25M | -3.05M | -4.64M | -4.12M |
| ChangeInPayablesAndAccruedExpense | -16.52M | 49.20M | -6.38M | 7.43M |
| ChangeInPayable | -16.52M | 49.20M | -6.38M | 7.43M |
| ChangeInAccountPayable | -16.52M | 49.20M | -6.38M | 7.43M |
| ChangeInPrepaidAssets | 13.96M | -8.06M | -6.19M | -5.92M |
| ChangeInInventory | -73.65M | -44.61M | -5.34M | -7.79M |
| ChangeInReceivables | -19.48M | -20.11M | -17.33M | -8.19M |
| ChangesInAccountReceivables | -19.48M | -20.11M | -17.33M | -8.19M |
| OtherNonCashItems | 2.26M | -16.15M | 3.71M | -1.35M |
| StockBasedCompensation | 84.91M | 86.08M | 76.51M | 57.84M |
| AssetImpairmentCharge | 9.21M | 2.73M | 18.18M | 0.00 |
| DeferredTax | 0.00 | -4.94M | 9.00K | 34.00K |
| DeferredIncomeTax | 0.00 | -4.94M | 9.00K | 34.00K |
| DepreciationAmortizationDepletion | 8.55M | 7.87M | 5.34M | 6.21M |
| DepreciationAndAmortization | 8.55M | 7.87M | 5.34M | 6.21M |
| OperatingGainsLosses | 16.23M | 33.55M | 6.12M | 3.82M |
| NetForeignCurrencyExchangeGainLoss | 16.23M | 19.61M | 6.12M | 3.56M |
| NetIncomeFromContinuingOperations | -56.11M | -151.58M | -236.57M | -250.46M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for FOLD
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|